Andrea Gil Guevara, MD
Neurology · Spartanburg, SCNPI 1467948927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,611, more than ten times the $195 reported in 2019.
Across 192 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$950
- Acadia Pharmaceuticals Inc$594
- AbbVie$567
- Neurocrine Biosciences, Inc.$405
- Pfizer$247
- AstraZeneca$246
- plus $2K from 33 others
What the payments were for
- Travel & lodging$4459%
- Food & beverage$4,54991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 8 | $950 |
| Acadia Pharmaceuticals Inc | 22 | $594 |
| AbbVie(2 entities) | 36 | $567 |
| Neurocrine Biosciences, Inc. | 24 | $405 |
| Pfizer | 22 | $247 |
| AstraZeneca(2 entities) | 9 | $246 |
| UCB, Inc. | 6 | $195 |
| Otsuka America Pharmaceutical, Inc. | 7 | $182 |
| Neuropace, Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 4 | $122 |
| Boston Scientific | 1 | $119 |
| Amgen | 3 | $113 |
| Argenx US, Inc. | 4 | $109 |
| Eisai Inc. | 4 | $106 |
| Biogen | 5 | $100 |
| EMD Serono, Inc. | 3 | $91 |
| Lilly USA, LLC | 4 | $73 |
| Kyowa Kirin, Inc. | 2 | $49 |
| CSL Behring | 2 | $48 |
| Genentech USA, Inc. | 2 | $46 |
| Bristol Myers Squibb | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Insightec,inc | 2 | $38 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Grifols USA, LLC | 1 | $25 |
| SK Life Science, Inc. | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Impel Pharmaceuticals LLC | 1 | $23 |
| Novartis | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,994 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 30 | $45,285 |
| Nurtec OdtRimegepant Sulfate | 30 | $44,784 |
| QuliptaAtogepant | 19 | $26,864 |
| AptiomEslicarbazepine Acetate | 11 | $26,259 |
| EliquisApixaban | 42 | $22,627 |
| VimpatLacosamide | 21 | $22,005 |
| XcopriCenobamate | 11 | $13,698 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $8,017 |
| Levetiracetam | 112 | $4,679 |
| Clobazam | 21 | $3,027 |
| Gabapentin | 141 | $2,392 |
| Duloxetine Hcl | 115 | $2,254 |
| Lacosamide | 27 | $2,088 |
| Pregabalin | 99 | $1,787 |
| Rasagiline Mesylate | 11 | $1,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $567 | $72,14849 claims |
| PfizerNurtec Odt, Eliquis | $247 | $67,41172 claims |
| UCB, Inc.Vimpat | $195 | $22,00521 claims |
| SK Life Science, Inc.Xcopri | $25 | $13,69811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.
Other neurology in Spartanburg
- Carol KooistraSpartanburg$29K
- Bogdan GheorghiuSpartanburg$23K
- Gonzalo ParesSpartanburg$10K
- Juliette SaadSpartanburg$9K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.